Nonoperative Management of a T1 Spinous Process Apophyseal Stress Fracture in an Adolescent Baseball Pitcher: A Case Report.

Int Med Case Rep JSep 15, 2026 (epub)
Case ReportOrthopedic SurgeryPediatricsRadiology (Diagnostic)Open access

Yuya Fukuda, Kinshi Kato, Kenichi Otoshi et al.

✦ AI-curated · Sources linked

Case in brief

A 13-year-old elite baseball pitcher presented with focal upper thoracic pain and no trauma history. MRI revealed an apophyseal stress fracture of the T1 spinous process. The patient was treated nonoperatively with rest and a gradual return-to-throwing program, leading to symptom resolution and return to competitive pitching in approximately 12 weeks. At 7-month follow-up, CT showed persistent apophyseal fragmentation without osseous union, but the patient remained asymptomatic.

Diagnostic / clinical pearl

MRI is crucial for early detection of thoracic apophyseal stress fractures in adolescent athletes, as clinical recovery can occur despite lack of radiologic union.

Source

PubMed · PMID 42763673Free full text on PubMed Central

Published in Int Med Case Rep J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.